Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-10-28
2008-09-02
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S007400
Reexamination Certificate
active
07419961
ABSTRACT:
Macrolides with anti-inflammatory activity are described. Particularly described are 9a-azalides and their anti-inflammatory activity without cladinose in position 3, the pharmaceutically acceptable salts thereof and the pharmaceutical composition that contain them as active principle.
REFERENCES:
patent: 3478014 (1969-11-01), Djokic et al.
patent: 3928387 (1975-12-01), Kierstead et al.
patent: 4328334 (1982-05-01), Kobrehel et al.
patent: 4464527 (1984-08-01), Bright
patent: 4886792 (1989-12-01), Djokic et al.
patent: 5250518 (1993-10-01), Kobrehel et al.
patent: 6262030 (2001-07-01), Wu et al.
patent: 6455576 (2002-09-01), Pellacini et al.
patent: 892357 (1982-07-01), None
patent: 0 771 564 (1997-05-01), None
patent: 0 775 489 (1997-05-01), None
patent: 20010301 (2001-04-01), None
patent: 92/16226 (1992-10-01), None
patent: 00/42055 (2000-07-01), None
M. T. Labro: Anti-inflammatory activity of macrolides: a new therapeutic potential? Journal of Antimicrobial Chemotherapy, vol. 41, Suppl. B, pp. 37-46, 1998.
Jun Tamaoki: “Effect of Erythromycin on Endotoxin-induced Microvascular Leakage in the Rat Trachea and Lungs” Am. J. Respir. Crit. Care Med., vol. 151, pp. 1582-1588, 1995.
Vera M. Keatings: “Differences in Interleukin-8 and Tumor Necrosis Factor-α in Induced Sputum from Patients with Chronic Obstructive Pulmonary Disease or Asthma” Am. J. Respir. Crit. Care Med., vol. 153, pp. 530-534, 1996.
Hajime Takizawa: “Erythromycin Modulates IL-8 Expression in Normal and Inflamed Human Bronchial Epithelial Cells” Am. J. Respir. Crit. Care Med., vol. 156, pp. 266-271, 1997.
Hiroyuki Miyatake et al.: “Erythromycin Reduces the Severity of Bronchial Hyperresponsiveness in Asthma” Chest, vol. 99, pp. 670-673, 1991.
Peter J. Barnes: “Mechanisms in COPD, Differences From Asthma” Chest, vol. 117, 2 Suppl., pp. 10S-14S, 2000.
Tomoko Suzuki: “Erythromycin and Common Cold in COPD” Chest, vol. 120, pp. 730-733, 2001.
Maric Therese Labro: “Immunomodulatory Actions of Antibacterial Agents” Clin. Immunother., vol. 6, pp. 454-464, 1996.
Slobodan Djokic et al.: “Erythromycin Series. Part 11. Ring Expansion of Erythromycin A Oxime by the Beckmann Rearrangement” J. Chem. Soc. Perkin Trans., pp. 1881-1890, 1986.
Viera Stvrtinova, Jan Jakubovsky and Ivan Hulin: “Inflammation and Fever” Academic Electronic Press, 1995.
Ronald Anderson: “Membrane-Stabilizing, Anti-Inflammatory Interactions of Macrolides With Human Neutrophils” Inflammation, vol. 20, No. 6, pp. 693-705, 1996.
Edwin H. Flynn: “Erythromycin. I. Properties and Degradation Studies” J. Am. Chem. Soc., vol. 76, pp. 3121-3131, 1954.
Jean-Claude Gasc et al.: “New Ether Oxime Derivatives of Erythromycin A, A Structure-Activity Relationship Study” The Journal of Antibiotics, vol. 44, pp. 313-330, 1991.
Crystal C. Koch: “Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects ofStreptococcus pneumoniae” Journal of Antimicrobial Chemotherapy, vol. 46, pp. 19-26, 2000.
Melita Zunic: “MDP(Lysyl)GDP, a Nontoxic Muramyl Dipeptide Derivative, Inhibits Cytokine Production by Activiated Macrophages and Protects Mice from Phrobol Ester- and Oxazolone-Induced Inflammation” The Society for Investigative Dermatology, Inc., vol. 111, No. 1, pp. 77-82, 1998.
Shin-ichi Konno: “Inhibition of Human T-Lymphocyte Activation by Macrolide Antibiotic, Roxithromycin” Life Sciences, vol. 51, pp. PL 231-236, 1992.
Partrick R. Murray, Ellen Jo Baron, Michael A. Pfaller, Fred C. Tenover and Robert H. Yolken: “Manual of Clinical Microbiology” American Society for Microbiology, 7thEdition, 1999.
Houria Abdelghaffar: “Erythromycin A-Derived Macrolides Modify the Functional Activities of Human Neutrophils by Altering the Phospholipase D-Phosphatidate Phosphohydrolase Transduction Pathway” The Journal of Immunology, vol. 159, pp. 3395-4005, 1997.
Adam Jaffe: “Long-term azithromycin may improve ling function in children with cystic fibrosis” The Lancet, vol. 351, p. 420, Feb. 7, 1998.
The Merck Index, XIII edition, No. 917, p. 159, 2001.
Hiroshi Koyama, Duncan M. Geddes: “Erythromycin and diffuse panbrochiolitis” Thorax, vol. 52, pp. 915-918, 1997.
Mereu Andrea
Morazzoni Gabriele
Moriggi Ermanno
Napoletano Mauro
Ornaghi Fernando
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Peselev Elli
Zambon S.p.A.
LandOfFree
9a-azalides with anti-inflammatory activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 9a-azalides with anti-inflammatory activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 9a-azalides with anti-inflammatory activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3989938